Mondrian Investment Partners LTD Cuts Stake in Kenvue Inc. (NYSE:KVUE)

Mondrian Investment Partners LTD reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 18.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,319,087 shares of the company’s stock after selling 1,212,908 shares during the period. Kenvue accounts for about 2.0% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 28th largest position. Mondrian Investment Partners LTD owned 0.28% of Kenvue worth $113,243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Assetmark Inc. raised its holdings in Kenvue by 29.9% in the third quarter. Assetmark Inc. now owns 67,796 shares of the company’s stock valued at $1,568,000 after buying an additional 15,593 shares during the period. Atria Investments Inc raised its holdings in Kenvue by 13.8% in the third quarter. Atria Investments Inc now owns 111,326 shares of the company’s stock valued at $2,575,000 after buying an additional 13,500 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Kenvue by 8.1% in the third quarter. Crossmark Global Holdings Inc. now owns 57,262 shares of the company’s stock valued at $1,324,000 after buying an additional 4,298 shares during the period. Los Angeles Capital Management LLC purchased a new position in Kenvue in the third quarter valued at approximately $213,000. Finally, Ashton Thomas Securities LLC purchased a new position in Kenvue in the third quarter valued at approximately $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.5 %

KVUE stock opened at $23.20 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $44.33 billion, a P/E ratio of 43.76, a PEG ratio of 2.62 and a beta of 1.25. The firm has a 50 day simple moving average of $21.81 and a 200-day simple moving average of $22.37.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.54%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of several research reports. UBS Group cut their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.